CD8A and cancer: Hence, our translational study uncovers that oncolytic adenoviral immunotherapy results in TIM-3 reduction and mitigation of T-cell exhaustion through induction of intratumoral CD8+ immune response, which correlates with improved overall survival in patients with cancer.